EE05320B1 - Eikosapentaeenhappe etlestri ja dokosaheksaeenhappe etlestri segu sisaldava essentsiaalse rasvhappe kasutamine - Google Patents
Eikosapentaeenhappe etlestri ja dokosaheksaeenhappe etlestri segu sisaldava essentsiaalse rasvhappe kasutamineInfo
- Publication number
- EE05320B1 EE05320B1 EEP200300297A EEP200300297A EE05320B1 EE 05320 B1 EE05320 B1 EE 05320B1 EE P200300297 A EEP200300297 A EE P200300297A EE P200300297 A EEP200300297 A EE P200300297A EE 05320 B1 EE05320 B1 EE 05320B1
- Authority
- EE
- Estonia
- Prior art keywords
- ester
- mixture
- acid
- fatty acids
- acids containing
- Prior art date
Links
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 title 2
- 150000002148 esters Chemical class 0.000 title 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 title 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 title 1
- 229940090949 docosahexaenoic acid Drugs 0.000 title 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 title 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 title 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 title 1
- 235000004626 essential fatty acids Nutrition 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001MI000129A ITMI20010129A1 (it) | 2001-01-25 | 2001-01-25 | Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco |
| PCT/EP2002/000507 WO2002058793A1 (en) | 2001-01-25 | 2002-01-16 | Essential n-3 fatty acids in cardiac insufficiency and heart failure therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EE200300297A EE200300297A (et) | 2003-10-15 |
| EE05320B1 true EE05320B1 (et) | 2010-08-16 |
Family
ID=11446587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200300297A EE05320B1 (et) | 2001-01-25 | 2002-01-16 | Eikosapentaeenhappe etlestri ja dokosaheksaeenhappe etlestri segu sisaldava essentsiaalse rasvhappe kasutamine |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20040077723A1 (cs) |
| EP (2) | EP2258447A3 (cs) |
| JP (1) | JP2004517148A (cs) |
| AU (1) | AU2002225026B2 (cs) |
| BG (1) | BG108071A (cs) |
| CA (1) | CA2433762A1 (cs) |
| CZ (1) | CZ20031947A3 (cs) |
| EA (1) | EA200300830A1 (cs) |
| EE (1) | EE05320B1 (cs) |
| HR (1) | HRP20030561A2 (cs) |
| HU (1) | HUP0303019A2 (cs) |
| IS (1) | IS6862A (cs) |
| IT (1) | ITMI20010129A1 (cs) |
| MX (1) | MX282405B (cs) |
| NO (1) | NO20033304D0 (cs) |
| NZ (1) | NZ526609A (cs) |
| PL (1) | PL363269A1 (cs) |
| SK (1) | SK8332003A3 (cs) |
| UA (1) | UA78693C2 (cs) |
| WO (1) | WO2002058793A1 (cs) |
| YU (1) | YU59303A (cs) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| ITMI20010129A1 (it) * | 2001-01-25 | 2002-07-25 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco |
| ITMI20012384A1 (it) * | 2001-11-12 | 2003-05-12 | Quatex Nv | Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori |
| ITMI20020269A1 (it) * | 2002-02-12 | 2003-08-12 | Victorix Assets Ltd | Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca |
| CA2506611A1 (en) * | 2002-11-22 | 2004-06-10 | Nippon Suisan Kaisha Ltd. | External composition containing polyunsaturated fatty acid or its salt or ester |
| ITMI20022511A1 (it) * | 2002-11-26 | 2004-05-27 | Victorix Assets Ltd | Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale. |
| PL1611088T3 (pl) * | 2003-04-07 | 2009-11-30 | Pharmacyclics Inc | Hydroksamiany jako środki terapeutyczne |
| WO2004091603A1 (fr) * | 2003-04-07 | 2004-10-28 | Clinigenetics | Utilisation d’un ester de dha pour le traitement des malades cardiovasculaires |
| SE0303513D0 (sv) * | 2003-12-19 | 2003-12-19 | Pronova Biocare As | Use of a fatty acid composition comprising at least one of epa and dha or any combinations thereof |
| CA2568640C (en) | 2004-06-04 | 2011-08-09 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
| EP1865770A4 (en) * | 2005-04-07 | 2010-12-29 | Nitromed Inc | ASSESSMENT OF GENETIC RISK IN CARDIAC ERRORS: IMPACT OF THE GENETIC VARIATION OF NOS3 |
| FR2902659A1 (fr) * | 2006-06-23 | 2007-12-28 | Pierre Fabre Medicament Sa | Ester de dha et son utilisation dans le traitement et la prevention des maladies cardiovasculaires |
| CA2692394A1 (en) * | 2007-07-06 | 2009-01-15 | Seth J. Baum | Fatty acid compositions and methods of use |
| US8877239B2 (en) | 2010-08-12 | 2014-11-04 | Nutritional Therapeutics, Inc. | Lipid supplements for maintaining health and treatment of acute and chronic disorders |
| US9468668B2 (en) | 2011-08-11 | 2016-10-18 | Allergy Research Group, Llc | Flavored chewable lipid supplements for maintaining health and the treatment of acute and chronic disorders |
| US8343753B2 (en) | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
| EP2323647B1 (en) | 2008-08-07 | 2014-09-10 | SPA SOCIETA' PRODOTTI ANTIBIOTICI S.p.A. | Long-term treatment of symptomatic heart failure |
| JPWO2010018856A1 (ja) * | 2008-08-13 | 2012-01-26 | 持田製薬株式会社 | カンナビノイド受容体関連疾患の予防／改善または治療剤 |
| EP4137128A1 (en) | 2008-09-02 | 2023-02-22 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and a statin, and methods of using same |
| ES2768091T3 (es) | 2009-02-10 | 2020-06-19 | Amarin Pharmaceuticals Ie Ltd | Uso del éster etílico del ácido eicosapentaenoico para tratar la hipertrigliceridemia |
| US9925162B2 (en) | 2009-04-09 | 2018-03-27 | The Regents Of The University Of Colorado | Methods and compositions for inducing physiological hypertrophy |
| MX350088B (es) | 2009-04-29 | 2017-08-25 | Amarin Pharma Inc | Composicion farmaceutica estable y metodos de uso de la misma. |
| NZ720946A (en) | 2009-04-29 | 2017-09-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| CN108096209A (zh) | 2009-06-15 | 2018-06-01 | 阿马里纳制药公司 | 在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法 |
| US20110071176A1 (en) | 2009-09-23 | 2011-03-24 | Amarin Pharma, Inc. | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| PH12012501755A1 (en) * | 2010-03-04 | 2012-11-12 | Amarin Pharma Inc | Compositions and methods for treating and/or preventing cardiovascular disease |
| NZ712068A (en) | 2010-11-29 | 2017-03-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| KR20140032380A (ko) * | 2011-02-07 | 2014-03-14 | 모찌다 세이야쿠 가부시끼가이샤 | 확장성 울혈성 심부전 치료제 |
| US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
| US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
| US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
| US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
| US11253531B2 (en) | 2011-08-11 | 2022-02-22 | Nutritional Therapeutics, Inc. | Lipid supplements for reducing nerve action potentials |
| US10117885B2 (en) | 2011-08-11 | 2018-11-06 | Allergy Research Group, Llc | Chewable lipid supplements for treating pain and fibromyalgia |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| ES2891473T3 (es) | 2012-01-06 | 2022-01-28 | Amarin Pharmaceuticals Ie Ltd | Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto |
| CA3067012C (en) | 2012-06-29 | 2021-10-05 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| KR20160063419A (ko) | 2013-01-10 | 2016-06-03 | 뉴트리셔널 테라퓨틱스, 인크. | 건강 유지 및 급성 및 만성 장애의 치료를 위한 지질 보조제를 함유하는 식용 웨이퍼 |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| MA51766A (fr) | 2018-09-24 | 2020-12-16 | Amarin Pharmaceuticals Ie Ltd | Procédés de réduction du risque d'événements cardiovasculaires chez un sujet |
| BR112022009189A2 (pt) | 2019-11-12 | 2022-07-26 | Amarin Pharmaceuticals Ie Ltd | Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial |
| US11986452B2 (en) | 2021-04-21 | 2024-05-21 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5735512A (en) | 1980-06-27 | 1982-02-26 | Nippon Oil & Fats Co Ltd | Preventive and remedy for thrombosis |
| NO157302C (no) | 1985-12-19 | 1988-02-24 | Norsk Hydro As | Fremgangsmaate for fremstilling av et fiskeoljekonsentrat. |
| US4920098A (en) * | 1986-09-17 | 1990-04-24 | Baxter International Inc. | Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases |
| IT1205043B (it) | 1987-05-28 | 1989-03-10 | Innova Di Ridolfi Flora & C S | Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri |
| GB2218984B (en) * | 1988-05-27 | 1992-09-23 | Renafield Limited | Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses |
| DD273852B3 (de) | 1988-07-07 | 1993-01-21 | Zentralinstitut Fuer Ernaehrun | Verfahren zur gewinnung und aufkonzentrierung polyenfettsaeurereicher lipide |
| GB8819110D0 (en) | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
| US6140304A (en) | 1988-09-28 | 2000-10-31 | Eicotech Corporation | Method of and nutritional and pharmaceutical compositions for reduction of hyperinsulinemia |
| JP3103588B2 (ja) | 1990-11-16 | 2000-10-30 | 持田製薬株式会社 | リポプロテイン（ａ）低下剤 |
| US5324323A (en) * | 1992-09-09 | 1994-06-28 | Telectronics Pacing Systems, Inc. | Multiple channel cardiosynchronous myoplasty apparatus |
| US5208236A (en) * | 1992-09-23 | 1993-05-04 | Schering Corporation | N-(acylaminomethyl)glutaryl amino acids and use |
| WO1994013642A1 (de) * | 1992-12-11 | 1994-06-23 | Ciba-Geigy Ag | Substituierte benzazepinone |
| CN1082909A (zh) | 1993-01-03 | 1994-03-02 | 潘玉珍 | 精制二十二碳六烯酸乙酯复合溶栓、抗痴呆药剂 |
| JPH06263634A (ja) | 1993-03-10 | 1994-09-20 | Sagami Chem Res Center | カルシウム拮抗薬 |
| JPH07118229A (ja) * | 1993-10-19 | 1995-05-09 | Fujisawa Pharmaceut Co Ltd | 尿素誘導体およびその製造法 |
| US5760081A (en) | 1994-05-10 | 1998-06-02 | The General Hospital Corporation | Omega 3 fatty acids in the prevention of ventricular fibrillation |
| JPH0812581A (ja) * | 1994-06-30 | 1996-01-16 | Fujirebio Inc | 虚血性心疾患治療剤 |
| JPH0853350A (ja) | 1994-08-11 | 1996-02-27 | Sagami Chem Res Center | 抗肺水腫薬 |
| IT1274734B (it) | 1994-08-25 | 1997-07-24 | Prospa Bv | Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti |
| JPH08151334A (ja) | 1994-11-25 | 1996-06-11 | Sagami Chem Res Center | リポソームおよびその製剤 |
| WO1998010085A2 (en) * | 1996-09-05 | 1998-03-12 | The Regents Of The University Of California | Gene therapy for congestive heart failure |
| GB9506837D0 (en) | 1995-04-03 | 1995-05-24 | Scotia Holdings Plc | Triglycerides |
| MY118354A (en) | 1995-05-01 | 2004-10-30 | Scarista Ltd | 1,3-propane diol derivatives as bioactive compounds |
| DK0760393T3 (da) | 1995-08-17 | 2003-09-29 | Hoffmann La Roche | Kromatografifremgangsmåde |
| IT1277953B1 (it) | 1995-12-21 | 1997-11-12 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per |
| US6333447B1 (en) * | 1996-03-29 | 2001-12-25 | The General Hospital Corporation | Transgenic model of heart failure |
| US5861399A (en) * | 1996-07-17 | 1999-01-19 | Heart Care Partners | Methods and compositions for the rapid and enduring relief of inadequate myocardial function |
| US6313167B1 (en) | 1997-06-16 | 2001-11-06 | Nippon Suisan Kaisha Ltd. | Composition having capability of removing risk factor during exercise |
| ES2289814T3 (es) * | 1998-07-10 | 2008-02-01 | Novartis Pharma Ag | Combinacion antihipertensiva de valsartan y bloqueador de canales del calcio. |
| IT1308613B1 (it) * | 1999-02-17 | 2002-01-09 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella prevenzione di eventi cardiovascolari. |
| GB9916536D0 (en) | 1999-07-14 | 1999-09-15 | Scarista Limited | Nutritional or pharmaceutical compositions |
| ES2159257B1 (es) | 1999-11-19 | 2002-04-16 | Kd Iqa S L | Nuevo procedimiento de preparacion del ester etilico del acido eicosa pentaenoico. |
| CA2291959A1 (en) | 1999-12-08 | 2001-06-08 | Alex P. Korn | A nutriceutical composition of l-carnitine, ubiquinone, n-3 polyunsaturated fatty acids and vitamins specifically formulated at pharmacological doses for the amelioration of the risk factors and symptoms of atherosclerosis-related illnesses |
| US8753675B1 (en) | 2000-01-20 | 2014-06-17 | Raj K. Chopra | Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications |
| EP1762557B1 (en) | 2000-02-16 | 2011-04-06 | The Brigham And Women's Hospital, Inc. | Aspirin-triggered lipid mediators |
| EP1130027A1 (de) * | 2000-02-29 | 2001-09-05 | Aventis Pharma Deutschland GmbH | Memno-Peptide, Verfahren zu ihrer Herstellung und Verwendung derselben |
| JP4139544B2 (ja) | 2000-03-06 | 2008-08-27 | 花王株式会社 | 血糖値低下剤 |
| CA2304906A1 (en) | 2000-04-07 | 2001-10-07 | 1411198 Ontario Limited | 13-hode, a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia |
| ES2246769T3 (es) | 2000-05-22 | 2006-03-01 | Pro Aparts - Investimentos E Consultoria Lda | Composicion de acidos grasos que contiene al menos 80% en peso de epa y dha o sus derivados y su uso farmaceutico. |
| GB0016045D0 (en) | 2000-06-29 | 2000-08-23 | Laxdale Limited | Therapeutic combinations of fatty acids |
| DE10056351A1 (de) | 2000-11-14 | 2002-05-29 | Weylandt Karsten Henrich | Pharmazeutisches Präparat |
| ITMI20010129A1 (it) * | 2001-01-25 | 2002-07-25 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco |
-
2001
- 2001-01-25 IT IT2001MI000129A patent/ITMI20010129A1/it unknown
-
2002
- 2002-01-16 NZ NZ526609A patent/NZ526609A/en not_active IP Right Cessation
- 2002-01-16 MX MXPA03006480 patent/MX282405B/es active IP Right Grant
- 2002-01-16 PL PL02363269A patent/PL363269A1/xx not_active Application Discontinuation
- 2002-01-16 EE EEP200300297A patent/EE05320B1/xx not_active IP Right Cessation
- 2002-01-16 AU AU2002225026A patent/AU2002225026B2/en not_active Ceased
- 2002-01-16 HR HR20030561A patent/HRP20030561A2/hr not_active Application Discontinuation
- 2002-01-16 CA CA002433762A patent/CA2433762A1/en not_active Abandoned
- 2002-01-16 WO PCT/EP2002/000507 patent/WO2002058793A1/en not_active Ceased
- 2002-01-16 YU YU59303A patent/YU59303A/sh unknown
- 2002-01-16 EP EP10183221A patent/EP2258447A3/en not_active Withdrawn
- 2002-01-16 UA UA2003087938A patent/UA78693C2/uk unknown
- 2002-01-16 EP EP02715455A patent/EP1365841A1/en not_active Ceased
- 2002-01-16 HU HU0303019A patent/HUP0303019A2/hu unknown
- 2002-01-16 EA EA200300830A patent/EA200300830A1/ru unknown
- 2002-01-16 JP JP2002559123A patent/JP2004517148A/ja active Pending
- 2002-01-16 SK SK833-2003A patent/SK8332003A3/sk not_active Application Discontinuation
- 2002-01-16 CZ CZ20031947A patent/CZ20031947A3/cs unknown
- 2002-01-16 US US10/451,623 patent/US20040077723A1/en not_active Abandoned
-
2003
- 2003-06-27 IS IS6862A patent/IS6862A/is unknown
- 2003-07-22 NO NO20033304A patent/NO20033304D0/no not_active Application Discontinuation
- 2003-08-07 BG BG108071A patent/BG108071A/bg unknown
-
2006
- 2006-01-17 US US11/333,387 patent/US7439267B2/en not_active Expired - Fee Related
-
2008
- 2008-09-09 US US12/207,068 patent/US20090005327A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1365841A1 (en) | 2003-12-03 |
| WO2002058793A1 (en) | 2002-08-01 |
| NZ526609A (en) | 2005-10-28 |
| EP2258447A2 (en) | 2010-12-08 |
| EE200300297A (et) | 2003-10-15 |
| EP2258447A3 (en) | 2012-07-25 |
| NO20033304L (no) | 2003-07-22 |
| NO20033304D0 (no) | 2003-07-22 |
| UA78693C2 (en) | 2007-04-25 |
| HRP20030561A2 (en) | 2005-06-30 |
| ITMI20010129A1 (it) | 2002-07-25 |
| YU59303A (sh) | 2006-08-17 |
| MXPA03006480A (es) | 2003-09-22 |
| SK8332003A3 (en) | 2003-11-04 |
| EA200300830A1 (ru) | 2003-12-25 |
| IS6862A (is) | 2003-06-27 |
| PL363269A1 (en) | 2004-11-15 |
| HUP0303019A2 (hu) | 2003-12-29 |
| US20060205814A1 (en) | 2006-09-14 |
| AU2002225026B2 (en) | 2007-09-13 |
| JP2004517148A (ja) | 2004-06-10 |
| US7439267B2 (en) | 2008-10-21 |
| CZ20031947A3 (cs) | 2003-12-17 |
| MX282405B (es) | 2010-12-21 |
| US20040077723A1 (en) | 2004-04-22 |
| US20090005327A1 (en) | 2009-01-01 |
| CA2433762A1 (en) | 2002-08-01 |
| BG108071A (bg) | 2005-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE200300297A (et) | Eikosapentaeenhappe etüülestri ja dokosaheksaeenhappe etüülestri segu sisaldava essentsiaalse rasvhappe kasutamine | |
| ATE216230T1 (de) | Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen | |
| PL359637A1 (en) | Method of manufacture of alkyl esters of fatty acids and high-purity glycerine | |
| EE200300030A (et) | 4-jodofenüülaminobenshüdroksaamhapete oksügeenitud estrid | |
| AU2001255337A8 (en) | Infant formulas containing long-chain polyunsaturated fatty acids and uses thereof | |
| DE60237148D1 (de) | Fettalkohole und fettsäureester zur behandlung von entzündungen | |
| ATE315388T1 (de) | Therapeutische kombinationen von fettsäuren | |
| ATE285783T1 (de) | Feste lipidformulierung enthaltend lipasehemmer und fettsäureester von polyolen | |
| PL359696A1 (en) | Isononyl esters of benzene carboxylic acid and their application | |
| AU5377400A (en) | Concentration and purification of polyunsaturated fatty acid esters by distillation-enzymatic transesterification coupling | |
| EP1801096A4 (en) | POLYGLYCERIN FUEL ACID AND THE COMPOSITIONS CONTAINING THEREOF | |
| EP1765324A4 (en) | COMPOSITIONS BASED ON STABLE BIOACTIVE METABOLITES OF DOCOSAHEXANOIC (DHA) AND EICOSAPENTANOIC ACIDS (EPA) | |
| IL158908A0 (en) | Pharmaceutical composition comprising a lipase inhibitor and a sucrose fatty acid ester | |
| AU2003292080A1 (en) | Use of pharmaceutical compositions containing ethyl esters of omega-3 polyunsaturated acids to prevent atrial fibrillation | |
| IL144573A0 (en) | Method for obtaining an oil that is rich in hydroxyoctadecadienoic fatty acids (hode) or the esters thereof from a mixture containing linoleic acid or the esters thereof | |
| AU2001259158A1 (en) | Treatment of skin damage using acetyl carnitine and phosphatidylcholine and/or ascorbyl fatty acid esters | |
| EP1696873A4 (en) | PREPARATION AND CLEANING OF ESTERS FROM CONJUGATED LINOLIC ACIDS | |
| DE60123564D1 (de) | Verfahren zur Herstellung von Estern ungesättigter Carbonsäuren | |
| HK1084865A (en) | Use of pharmaceutical compositions containing ethyl esters of omega-3 polyunsaturated acids to prevent atrial fibrillation | |
| PL346802A1 (en) | Novel amino esters of fatty acids | |
| SK2252U (sk) | Zariadenie na kontinuálnu esterifikáciu mastných kyselín | |
| PL356222A1 (en) | Method of manufacture of esters of higher fatty acids | |
| NO20022578D0 (no) | Fosfolipider inneholdende omega-3 fettsyrer | |
| IL158228A0 (en) | Use of esters of long-chain fatty acids for treatment of autoimmune diseases | |
| AU2002357948A1 (en) | Esterification of fatty acids in oil |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB4A | Valid patent at the end of a year |
Effective date: 20101231 |
|
| MM4A | Lapsed by not paying the annual fees |
Effective date: 20140116 |